PT1848813E - Activação de glicolípidos bacterianos de células nkt restritas ao cd1d - Google Patents

Activação de glicolípidos bacterianos de células nkt restritas ao cd1d Download PDF

Info

Publication number
PT1848813E
PT1848813E PT67339218T PT06733921T PT1848813E PT 1848813 E PT1848813 E PT 1848813E PT 67339218 T PT67339218 T PT 67339218T PT 06733921 T PT06733921 T PT 06733921T PT 1848813 E PT1848813 E PT 1848813E
Authority
PT
Portugal
Prior art keywords
glycolipid
cells
alkyl
nkt
cell
Prior art date
Application number
PT67339218T
Other languages
English (en)
Portuguese (pt)
Inventor
Luc Teyton
Albert Bendelac
Paul Savage
Original Assignee
Scripps Research Inst
Univ Chicago
Univ Brigham Young
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Univ Chicago, Univ Brigham Young filed Critical Scripps Research Inst
Publication of PT1848813E publication Critical patent/PT1848813E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT67339218T 2005-01-28 2006-01-26 Activação de glicolípidos bacterianos de células nkt restritas ao cd1d PT1848813E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64815305P 2005-01-28 2005-01-28

Publications (1)

Publication Number Publication Date
PT1848813E true PT1848813E (pt) 2013-07-15

Family

ID=36777772

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67339218T PT1848813E (pt) 2005-01-28 2006-01-26 Activação de glicolípidos bacterianos de células nkt restritas ao cd1d

Country Status (12)

Country Link
US (1) US9295722B2 (enExample)
EP (1) EP1848813B1 (enExample)
JP (1) JP5053101B2 (enExample)
AU (1) AU2006211485B2 (enExample)
BR (1) BRPI0607299A2 (enExample)
CA (1) CA2593715C (enExample)
DK (1) DK1848813T3 (enExample)
ES (1) ES2423005T3 (enExample)
PL (1) PL1848813T3 (enExample)
PT (1) PT1848813E (enExample)
WO (1) WO2006083671A2 (enExample)
ZA (1) ZA200706208B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
WO2007118234A2 (en) 2006-04-07 2007-10-18 The Scripps Research Institute Modified -galactosyl ceramides for staining and stimulating natural killer t cells
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
WO2008128207A1 (en) * 2007-04-13 2008-10-23 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
AU2013202865B2 (en) * 2007-11-07 2015-03-19 Abivax Increase of immune response and targeting by antigens and/or drug linkage
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
EP2060252A1 (en) 2007-11-19 2009-05-20 Wittycell New formulation of galactosylceramide derivatives
BRPI0820960B8 (pt) * 2007-12-05 2021-05-25 Abivax composição, composição farmacêutica, e uso da composição
US9220767B2 (en) 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
CN115666586A (zh) * 2020-04-23 2023-01-31 加州大学评议会 通过激活iNKT细胞清除衰老细胞
KR20230119224A (ko) * 2020-12-18 2023-08-16 로레알 스핑고모나스 속 박테리아 추출물
FR3117776B1 (fr) * 2020-12-18 2024-03-08 Oreal Extrait de bactérie du genreSphingomonas
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
WO2024107463A1 (en) * 2022-11-14 2024-05-23 The Trustees Of Columbia University In The City Of New York 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (enExample) 1992-07-16 1995-11-01 Kirin Brewery
ATE191916T1 (de) 1992-10-22 2000-05-15 Kirin Brewery Neues sphingolglycolipid und verwendung davon
US5780441A (en) 1993-04-15 1998-07-14 Kirin Beer Kabushiki Kaisha Sphingoglycolipid compounds and therapeutic uses thereof
CN1125449A (zh) 1993-05-14 1996-06-26 萨依特尔有限公司 作为细胞粘附抑制剂的唾液基Lex类似物
EP1520583B1 (en) 1997-04-10 2009-01-28 Kyowa Hakko Kirin Co., Ltd. NKT cell-activating agents containing alpha-glycosylceramides
EP1011719A1 (en) * 1997-09-12 2000-06-28 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
US20030153514A1 (en) 2000-04-28 2003-08-14 Akikuni Yagita Remedies for cancer
US20020071842A1 (en) * 2000-06-05 2002-06-13 Gumperz Jenny E. Soluble CD1 compositions and uses thereof
EP1297017B1 (en) * 2000-06-19 2012-06-13 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AU2002327338A1 (en) 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
CN1578667A (zh) 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2004094444A1 (en) 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
DK1786439T3 (da) 2004-09-03 2010-07-12 Univ Chicago Fremgangsmåder til aktivering af NKT-celler
WO2007118234A2 (en) 2006-04-07 2007-10-18 The Scripps Research Institute Modified -galactosyl ceramides for staining and stimulating natural killer t cells
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use

Also Published As

Publication number Publication date
PL1848813T3 (pl) 2013-09-30
WO2006083671A2 (en) 2006-08-10
US9295722B2 (en) 2016-03-29
BRPI0607299A2 (pt) 2009-08-25
JP5053101B2 (ja) 2012-10-17
EP1848813A2 (en) 2007-10-31
AU2006211485B2 (en) 2011-04-14
US20080279894A1 (en) 2008-11-13
JP2008528608A (ja) 2008-07-31
CA2593715C (en) 2015-05-05
AU2006211485A1 (en) 2006-08-10
DK1848813T3 (da) 2013-07-15
ZA200706208B (en) 2008-04-30
EP1848813B1 (en) 2013-04-10
EP1848813A4 (en) 2008-07-09
ES2423005T3 (es) 2013-09-17
WO2006083671B1 (en) 2007-04-12
WO2006083671A3 (en) 2007-02-22
CA2593715A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
EP1848813B1 (en) Bacterial glycolipid activation of cd1d-restricted nkt cells
Chang et al. Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity
Wesch et al. Modulation of γδ T cell responses by TLR ligands
Carreño et al. Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents
JP2010523724A (ja) α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用
Duramad et al. Pharmacologic expansion of donor-derived, naturally occurring CD4+ Foxp3+ regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models
KR20120061045A (ko) 오크로박트룸 인터미디움의 지질다당류 및 포유동물의 면역자극제로서 그의 용도
Haque et al. Neem (Azadirachta indica) leaf preparation induces prophylactic growth inhibition of murine Ehrlich carcinoma in Swiss and C57BL/6 mice by activation of NK cells and NK-T cells
Hogan et al. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide
Yuan et al. A Streptococcus pneumoniae endolysin mutant protein ΔA146Ply elicits rapid broad-spectrum mucosal protection in mice via upregulation of GPX4 through TLR4/IRG1/NRF2 to alleviate macrophage ferroptosis
Montalvillo et al. Innate lymphoid cells and natural killer T cells in the gastrointestinal tract immune system
Fujiwara et al. Bacterial sphingophospholipids containing non-hydroxy fatty acid activate murine macrophages via Toll-like receptor 4 and stimulate bacterial clearance
Ongol et al. Potential of selected strains of lactic acid bacteria to induce a Th1 immune profile
Saito et al. Protective and therapeutic efficacy of Lactobacillus casei against experimental murine infections due to Mycobacterium fortuitum complex
US7928088B2 (en) Th1 cell differentiation accelerator
Hart Increased sensitivity of Corynebacterium parvum-treated mice to toxic effects of indomethacin and lipopolysaccharide
Nasrallah et al. Comparative effects of different strains of Corynebacterium parvum on natural cell-mediated cytotoxicity
Ohtsubo et al. Growth inhibition of tumour cells by a liposome-encapsulated, mycolic acid-containing glycolipid, trehalose 2, 3, 6'-trimycolate
Matham et al. Immune targets druggability of mycoplasma synoviae in chicken
McPherson Evaluation of the Mode of Action of Sulfated Lactosyl Archaeol Adjuvant: Interaction with L-selectin and Impact of Administration Route
Mierzejewska et al. De-O-acylated lipooligosaccharide of E. coli B reduces the number of metastatic foci via downregulation of myeloid cell activity
Bhattcharya Immunology and Microbiology
US20080152626A1 (en) Method for Activating Cd8 T Cells
Alley et al. Effect of inoculation with neuraminidase-treated tumor cells on macrophage cytotoxicity in vitro
Martner Regulation of innate and adaptive immune responses by Gram-positive and Gram-negative bacteria